Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond
Standard
Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond. / Bianchi, Alberto; von Deimling, Markus; Pallauf, Maximilian; Yanagisawa, Takafumi; Kawada, Tatsushi; Mostafaei, Hadi; Quhal, Fahad; Laukhtina, Ekaterina; Rajwa, Pawel; Majdoub, Muhammad; Sari Motlagh, Reza; Pradère, Benjamin; Karakiewicz, Pierre I; Cerruto, Maria Angela; Antonelli, Alessandro; Shariat, Shahrokh F.
In: EXPERT OPIN PHARMACO, Vol. 24, No. 2, 02.2023, p. 177-195.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond
AU - Bianchi, Alberto
AU - von Deimling, Markus
AU - Pallauf, Maximilian
AU - Yanagisawa, Takafumi
AU - Kawada, Tatsushi
AU - Mostafaei, Hadi
AU - Quhal, Fahad
AU - Laukhtina, Ekaterina
AU - Rajwa, Pawel
AU - Majdoub, Muhammad
AU - Sari Motlagh, Reza
AU - Pradère, Benjamin
AU - Karakiewicz, Pierre I
AU - Cerruto, Maria Angela
AU - Antonelli, Alessandro
AU - Shariat, Shahrokh F
PY - 2023/2
Y1 - 2023/2
N2 - INTRODUCTION: Despite recent developments in the landscape of urothelial carcinoma (UC) treatment, platinum combination chemotherapy still remains a milestone. Recently immunotherapeutic agents have gained ever-growing attractivity, particularly in the metastatic setting. Novel chemotherapeutic strategies and agents, such as antibody-drug conjugates (ADCs), and powerful combination regimens have been developed to overcome the resistance of most UC to current therapies.AREAS COVERED: Herein, we review the current standard-of-care chemotherapy, the development of ADCs, the rationale for combining therapy regimens with chemotherapy in current trials, and future directions in UC management.EXPERT OPINION: Immunotherapy has prompted a revolution in the treatment paradigm of UC. However, only a few patients experience a long-term response when treated with single-agent immunotherapies. Combination treatments are necessary to bypass resistance mechanisms and broaden the clinical utility of current options. Current evidence supports the intensification of standard-of-care chemotherapy with maintenance immunotherapy. However, the optimal sequence, combination, and duration must be determined to achieve individual longevity with acceptable health-related quality of life. In that regard, ADCs appear as a promising alternative for single and combination strategies in UC, as they specifically target the tumor cells, thereby, theoretically improving treatment efficacy and avoiding extensive off-target toxicities.
AB - INTRODUCTION: Despite recent developments in the landscape of urothelial carcinoma (UC) treatment, platinum combination chemotherapy still remains a milestone. Recently immunotherapeutic agents have gained ever-growing attractivity, particularly in the metastatic setting. Novel chemotherapeutic strategies and agents, such as antibody-drug conjugates (ADCs), and powerful combination regimens have been developed to overcome the resistance of most UC to current therapies.AREAS COVERED: Herein, we review the current standard-of-care chemotherapy, the development of ADCs, the rationale for combining therapy regimens with chemotherapy in current trials, and future directions in UC management.EXPERT OPINION: Immunotherapy has prompted a revolution in the treatment paradigm of UC. However, only a few patients experience a long-term response when treated with single-agent immunotherapies. Combination treatments are necessary to bypass resistance mechanisms and broaden the clinical utility of current options. Current evidence supports the intensification of standard-of-care chemotherapy with maintenance immunotherapy. However, the optimal sequence, combination, and duration must be determined to achieve individual longevity with acceptable health-related quality of life. In that regard, ADCs appear as a promising alternative for single and combination strategies in UC, as they specifically target the tumor cells, thereby, theoretically improving treatment efficacy and avoiding extensive off-target toxicities.
KW - Antineoplastic Agents/therapeutic use
KW - Carcinoma, Transitional Cell/drug therapy
KW - Humans
KW - Immunotherapy
KW - Quality of Life
KW - Urinary Bladder Neoplasms/drug therapy
U2 - 10.1080/14656566.2022.2150966
DO - 10.1080/14656566.2022.2150966
M3 - SCORING: Review article
C2 - 36440477
VL - 24
SP - 177
EP - 195
JO - EXPERT OPIN PHARMACO
JF - EXPERT OPIN PHARMACO
SN - 1465-6566
IS - 2
ER -